Everything about Hereditary Hemorrhagic Telangiectasia totally explained
In
medicine,
hereditary hemorrhagic telangiectasia (HHT), also known as
Osler-Weber-Rendu syndrome, is an
autosomal dominant genetic disorder that leads to
vascular malformations.
Signs and symptoms
HHT is characterised by
telangiectasia (small vascular malformations) on the skin and mucosal linings,
epistaxis (nosebleeds), and
arteriovenous malformations (AVMs) in various internal organs.
Skin and mucosa telangiectasias are most remarkable on the tongue, hands/fingers, nose, lips, mouth/throat and
conjunctiva.
The internal organs that can harbor AVMs often include the
brain and
lungs. In both, bleeding can seriously endanger life.
Anemia may occur due to bleeding from digestive tract AVMs.
Congestive cardiac failure (high-output heart failure) may develop in the presence of marked shunting arterial blood to the venous circulation, for example when AVMs are present in the
liver.
Diagnosis
There are four diagnostic criteria. If three or four are met, a patient has
definite HHT, while two gives a possible diagnosis:
- Spontaneous recurrent epistaxis
- Multiple teleangiectasias on typical locations (see above)
- Proven visceral AVM (lung, liver, brain, spine)
- First-degree family member with HHT
When HHT is suspected,
physical examination focuses on inspecting the whole skin for teleangiectasias,
auscultation of the lungs and liver, and
neurological examination.
Pulmonary AVMs can be anticipated by measuring
oxygen levels and performing
arterial blood gas (ABG) sampling. An
X-ray of the chest can show susceptible lesions; in addition, low oxygen tension (<96% or a 2% decrease upon standing) or low blood oxygen levels on ABG are required for a diagnosis.
Genetics
HHT is a
genetic disorder by definition. It is inherited in an
autosomal dominant manner.
Four forms have been described:
HHT1: mutation of the endoglin gene (ninth chromosome). Endoglin is a receptor of TGFβ1 (transforming growth factor beta 1) and TGFβ3. It also interacts with zyxin and ZRP-1 with its intracellular domain, to control composition of focal adhesions and regulate organization of actin filaments. This form predisposes for pulmonary AVMs and early nosebleeds.
HHT2: mutation in the alk1 gene (12th chromosome). Alk-1 (activin receptor-like kinase 1) is a TGFβ1 receptor. Less pulmonary AVMs and later nosebleeds, but an increased risk of pulmonary hypertension (supposedly due to altered TGFβ signalling or other related pathways which may lead to vascular malformations).
HHT3: a third form has been suspected to exist, but hasn't yet been linked to a defective gene. Current research is focused upon chromosome 5.
Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome is caused by mutations in the gene SMAD4
HHT4 has been identified in September 2006. The search for the gene associated with HHT4 is ongoing, with current research focused upon chromosome 7.
It is possible to test patients for the presence of mutations in endoglin, ALK-1 and SMAD4. When the mutation in an affected family member has been found it's possible to test other family members and identify those people not at risk for developing the disease.
Pathophysiology
The mechanism underlying the formation of vascular malformations isn't completely understood, but signalling of transforming growth factor-β1 is most likely to be involved. Possibly, connective tissue is required to support and guide proliferating blood vessels during angiogenesis, and defects in TGF-β signalling adversely affect connective tissue and matrix production.
Treatment
There is no specific treatment for the condition. Anemia due to bleeding from digestive tract AVMs often necessitates repeated blood transfusions. AVMs in critical organs often necessitates surgery. If major AVMs are all the patient has in terms of long-term problems, the surgery performed will block the malformed arteries, ruling out the risk for stroke and blood-clots. This surgery will hopefully lead to a normal life for the patient, and also help doctors diagnose patients with HHT more easily around the globe.
Epidemiology
HHT occurs mainly in whites (1:5,000), more in certain areas of France, but much less in blacks (1 in million). It is found in all continents throughout the world. It is also seen with increased frequency in Mormon families from Utah.
Further Information
Get more info on 'Hereditary Hemorrhagic Telangiectasia'.
|
External Link Exchanges
Do you know how hard it is to get a link from a large encyclopaedia? Well we're different and will prove it. To get a link from us just add the following HTML to your site on a relevant page:
<a href="http://hereditary_hemorrhagic_telangiectasia.totallyexplained.com">Hereditary hemorrhagic telangiectasia Totally Explained</a>
Then simply click through this link from your web page. Our crawlers will verify your link, extract the title of your web page and instantly add a link back to it. If you like you can remove the words Totally Explained and embed the link in article text.
As long as your link remains in place, we'll keep our link to you right here. Please play fair - our crawlers are watching. Your site must be closely related to this one's topic. Any kind of spamming, dubious practises or removing the link will result in your link from us being dropped and, potentially, your whole site being banned. |